4-aminobenzoic acid has been researched along with cyclin d1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhat, HK; Bhat, NK; Chatterjee, A; Dandawate, P; Murphy, L; Padhye, S; Ronghe, A; Singh, B | 1 |
| Civelli, M; Facchinetti, F; Pambianchi, E; Sticozzi, C; Valacchi, G; Villetti, G; Woodby, B | 1 |
2 other study(ies) available for 4-aminobenzoic acid and cyclin d1
| Article | Year |
|---|---|
Differential regulation of estrogen receptors α and β by 4-(E)-{(4-hydroxyphenylimino)-methylbenzene,1,2-diol}, a novel resveratrol analog.
Topics: Antineoplastic Agents; Catechols; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Molecular Docking Simulation; para-Aminobenzoates; Proto-Oncogene Proteins c-myc; Resveratrol; RNA, Messenger; Schiff Bases; Stilbenes | 2014 |
The PDE4 inhibitor CHF6001 affects keratinocyte proliferation via cellular redox pathways.
Topics: Aldehydes; Cell Line; Cell Proliferation; Cell Survival; Cyclin D1; Humans; Keratinocytes; Lipid Peroxidation; NADPH Oxidases; Oxidative Stress; para-Aminobenzoates; Phosphodiesterase 4 Inhibitors; Psoriasis; Sulfonamides; Transcription Factor RelA | 2020 |